FDA Orange Book

Is there a generic for Ilevro?

Ilevro contains nepafenac. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.

Source: FDA Orange Book data file dated 2026-10-09. Publisher page

No. The Orange Book lists no active FDA-approved generic (ANDA) for Ilevro (nepafenac). The Orange Book shows its last listed patent expires March 31, 2032.

Run it in Rivvi

Map Ilevro and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Ilevro products in the Orange Book

Ilevro products and approved generics
Form and routeStrengthBrand statusBrand TEActive genericsGeneric TE codes
suspension/drops, ophthalmic0.3%Marketed (Rx)None0None

NDA 203491, held by HARROW EYE LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Ilevro patents

Patents listed for Ilevro
PatentExpiresCoversUse codeNDA
9662398December 1, 2030Drug productNone203491
8921337March 31, 2032Drug productNone203491

Ilevro NDC codes

Questions

Is there a generic for Ilevro?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Ilevro (nepafenac). The Orange Book shows its last listed patent expires March 31, 2032.

What is the generic name for Ilevro?

The active ingredient in Ilevro is nepafenac, per the FDA Orange Book.

When does the Ilevro patent expire?

The last patent listed for Ilevro in the Orange Book expires March 31, 2032. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.

More on Ilevro and Nepafenac

Try it on your own data today.

Free to start. Most teams are using it the same day.